

Special Issue

Innovations in Active Surveillance Management of Early Prostate Cancer

Message from the Guest Editor

Prostate cancer is the most common cancer diagnosed in the West and the second most common male cancer globally. The majority of diagnosed men, however, will live with rather than die from prostate cancer. For many men, treatment may in fact only bring harm without any tangible survival benefit. Active surveillance is a disease management strategy that monitors early prostate cancer with a low probability of ever causing harm in a patient's natural lifetime. In modern PSA-detected prostate cancer populations, up to a quarter of men diagnosed may be eligible for active surveillance. Despite its importance as a management option in clinical practice, most academic literature on active surveillance is based on data extrapolated from other treatments or from expert/consensus opinion. In this Special Issue of *Cancers*, we seek to address this evidence gap by highlighting research that has been based on investigating cohorts of men on surveillance and in whom clinic-pathological features, prediction tools, imaging, or biomarkers have been tested and explored. For more information, please visit the Special Issue website.

Guest Editor

Prof. Dr. Vincent J. Gnanapragasam

1. Cambridge Prostate Cancer Research and Clinical Trials Group, Cambridge, UK
2. Department of Surgery, University of Cambridge, Cambridge, UK
3. Department of Urology, Cambridge University Hospitals, Cambridge, UK

Deadline for manuscript submissions

8 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/250478

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)